CITI/CALL/GILEAD SCIENCES/110/0.1/19.06.25 | Market Closed - Deutsche Boerse AG 11:08:25 17/05/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -96.67% | ||
| 6 months | -99.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.001 | 0.00% |
| 16/24/16 | 0.001 | 0.00% |
| 15/24/15 | 0.001 | 0.00% |
| 14/24/14 | 0.001 | 0.00% |
| 13/24/13 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 11:08 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH6VWX |
| ISIN | DE000KH6VWX7 |
| Date issued | 20/06/2023 |
| Strike | 110 $ |
| Maturity | 19/06/2025 (398 Days) |
| Parity | 10 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.27 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
- Stock Market
- Warrants
- Warrant
